EXPAREL
®
(bupivacaine liposome injectable suspension)
Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing bunionectomy and
hemorrhoidectomy procedures.
The clinical benefit of the attendant decrease in opioid consumption was not demonstrated.
Important Safety Information:
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in
patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may cause an
immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may
follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not
be administered within 96 hours following administration of EXPAREL. Monitoring of cardiovascular and neurological
status, as well as vital signs should be performed during and after injection of EXPAREL as with other local anesthetic
products. Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should
be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability
to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations. In clinical
trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea,
constipation, and vomiting.
References: 1. Gorfine SR et al. Dis Colon Rectum. 2011;54(12):1552-1592. 2. Golf M et al. Adv Ther. 2011;28(9):776-788.
For the Management of Postsurgical Pain
Long-Lasting Pain Control With
Less Need for Opioids
1,2
> Indicated for administration into the surgical site
to produce postsurgical analgesia
> Reduce pain and opioid requirements
1,2
without
the need for catheters or pumps
©2014 Pacira Pharmaceuticals, Inc., Parsippany, NJ 07054 PP-EX-US-0501 11/14
Please see brief summary of Prescribing Information on reverse side.
For more information, visit www.EXPAREL.com
Patient-Focused
Pain Control With
A Single Dose